For years, researchers have been looking for new options for patients with advanced pancreatic cancer whose disease has progressed after receiving first-line treatments. ONIVYDE provides hope and a new treatment option for patients battling this disease.
Canadian patients and caregivers have the opportunity to provide input to the panCanadian Oncology Drug Review (pCODR), the agency that will recommend (or not) whether ONIVYDE (irinotecan liposome injection) will be funded for metastatic pancreatic patients who are not responding to other therapies.
Your support is vital … the more people who participate in this survey, the better the data! You do not need to have experienced ONIVYDE to participate. All entries are anonymous and the deadline is May 5, 2017.
To get started, please click on the Online Survey button below. Si vous aimeriez remplir une version française de ce sondage, veuillez cliquer ici.
